

Study	Total number of treatments	Risk as treatments with AE per 100 treatments [95%-CI]									
		Bleeding	Pain	Other local AE	Vegetative nervous system	Aggravation of symptoms	Central nervous system	Peripheral nervous system	Distant pain	Gastrointestinal /gynaecological AE	Unclassified AE
Yamashita 2000	1441	45.45 [42.89; 48.03]	15.75 [13.92; 17.68]	0.90 [0.48; 1.46]	4.72 [3.69; 5.87]	1.11 [0.63; 1.72]	0.35 [0.11; 0.72]		0.07 [0.00; 0.27]		
daSilva 2014	13884	4.11 [3.79; 4.45]	3.02 [2.74; 3.31]	0.43 [0.33; 0.55]	0.02 [0.00; 0.05]		0.01 [0.00; 0.03]	0.11 [0.06; 0.17]		0.04 [0.01; 0.07]	
Melchart 1998	1200	0.33 [0.09; 0.74]	4.17 [3.11; 5.37]	0.17 [0.02; 0.48]	2.58 [1.76; 3.56]	1.75 [1.09; 2.57]	0.25 [0.05; 0.61]	0.08 [0.00; 0.33]	0.08 [0.00; 0.33]	0.42 [0.13; 0.86]	
MacPherson 2005	9408	4.72 [4.30; 5.16]	12.27 [11.61; 12.94]	0.26 [0.16; 0.37]	27.87 [26.97; 28.78]	1.75 [1.50; 2.03]		0.35 [0.24; 0.48]	4.49 [4.08; 4.91]	1.18 [0.97; 1.41]	0.35 [0.24; 0.48]
Furuse 2017	14039	3.16 [2.88; 3.46]	1.25 [1.07; 1.44]	0.09 [0.04; 0.14]	0.63 [0.51; 0.77]	0.20 [0.13; 0.28]	0.09 [0.05; 0.15]	0.07 [0.03; 0.12]		0.10 [0.05; 0.16]	0.20 [0.13; 0.28]
Ernst 2003	3535	5.18 [4.47; 5.93]	1.30 [0.95; 1.70]	0.08 [0.02; 0.21]	2.46 [1.98; 3.00]	0.25 [0.12; 0.45]	1.08 [0.76; 1.44]	1.44 [1.08; 1.86]		0.34 [0.17; 0.56]	5.46 [4.74; 6.23]
Odsberg 2001	9277	18.44 [17.66; 19.24]	0.08 [0.03; 0.14]	0.05 [0.02; 0.11]	1.42 [1.19; 1.67]	2.33 [2.03; 2.65]	0.18 [0.11; 0.28]	0.01 [0.00; 0.04]		0.02 [0.00; 0.06]	0.06 [0.02; 0.13]
Yamashita 1999	65482	0.03 [0.02; 0.05]	0.01 [0.00; 0.02]	0.00 [0.00; 0.01]	0.00 [0.00; 0.01]	0.00 [0.00; 0.01]	0.01 [0.00; 0.02]	0.00 [0.00; 0.01]		0.01 [0.00; 0.02]	0.00 [0.00; 0.01]
Park 2009	1095	8.40 [6.83; 10.12]	3.38 [2.39; 4.53]		3.11 [2.16; 4.21]		0.82 [0.37; 1.44]	1.46 [0.84; 2.26]			0.46 [0.14; 0.94]
Leung 2009	2000	0.40 [0.17; 0.72]									
Park 2010	3071	1.95 [1.49; 2.47]	0.49 [0.27; 0.77]	0.10 [0.02; 0.24]	0.75 [0.66; 0.85]	0.07 [0.01; 0.19]	0.03 [0.00; 0.13]	0.26 [0.11; 0.47]		0.03 [0.00; 0.13]	0.03 [0.00; 0.13]
White 2001	31822	3.09 [2.90; 3.28]	1.15 [1.04; 1.27]	0.10 [0.07; 0.13]	4.73 [4.50; 4.95]	0.98 [0.87; 1.09]	0.01 [0.00; 0.03]	0.00 [0.00; 0.01]		0.02 [0.01; 0.04]	0.46 [0.39; 0.54]
MacPherson 2001	34407	2.08 [1.93; 2.23]	1.24 [1.12; 1.35]	0.01 [0.00; 0.02]	4.73 [4.50; 4.95]	2.83 [2.66; 3.01]	0.63 [0.55; 0.71]		0.51 [0.44; 0.59]	0.31 [0.25; 0.37]	0.86 [0.76; 0.96]
Fixed effect		1.87 [1.80; 1.93]	0.82 [0.78; 0.87]	0.05 [0.04; 0.06]	1.08 [1.04; 1.13]	0.58 [0.55; 0.62]	0.09 [0.07; 0.10]	0.03 [0.02; 0.04]	0.96 [0.87; 1.05]	0.08 [0.07; 0.09]	0.23 [0.20; 0.25]
Random effect		4.92 [1.18; 11.01]	2.43 [0.63; 5.35]	0.13 [0.04; 0.27]	2.24 [0.21; 6.35]	0.84 [0.26; 1.75]	0.20 [0.05; 0.46]	0.19 [0.02; 0.55]	0.73 [0.00; 5.02]	0.15 [0.03; 0.38]	0.47 [0.03; 1.46]
tau ²		0.0169	0.0095	0.0004	0.0213	0.0055	0.0011	0.0008	0.0085	0.0008	0.0025
I ²		99.9% [99.9%; 99.9%]	99.8% [99.8%; 99.8%]	96.4% [94.9%; 97.4%]	99.9% [99.9%; 99.9%]	99.7% [99.6%; 99.7%]	98.4% [97.9%; 98.8%]	97.5% [96.6%; 98.2%]	99.5% [99.4%; 99.7%]	98.2% [97.6%; 98.6%]	99.4% [99.2%; 99.5%]
p-value Q-test		< 0.0001	< 0.0001	0.0001	< 0.0001	< 0.0001	0.0001	< 0.0001	0.0001	0.0001	0.0001

Study	Total number of treatments	Risk as treatments with AE per 100 treatments [95%-CI]							
		Headache	Cardiovascular system	Motor system	Generalized skin reaction	Needling malpractice	Emotional interference	Sleeping problems	Moxibustion AE
Yamashita2000	1441	0.14 [0.01; 0.40]				0.62 [0.28; 1.10]			
daSilva2014	13884					0.24 [0.16; 0.33]			
Meilchart1998	1200		0.08 [0.00; 0.33]				0.08 [0.00; 0.33]		
MacPherson2005	9408						0.67 [0.51; 0.84]		
Furuse2017	14039	0.01 [0.00; 0.03]	0.01 [0.00; 0.04]			0.10 [0.05; 0.16]		0.17 [0.11; 0.25]	
Ernst2003	3535	0.06 [0.01; 0.16]	0.06 [0.01; 0.16]	0.03 [0.00; 0.11]			0.11 [0.03; 0.25]		0.03 [0.00; 0.11]
Odsberg2001	9277	0.05 [0.02; 0.11]		0.01 [0.00; 0.04]			0.04 [0.01; 0.10]		
Yamashita1999	65482					0.04 [0.03; 0.06]	0.01 [0.00; 0.02]	0.01 [0.00; 0.02]	
Park2009	1095								
Leung2009	2000								
Park2010	3071	0.03 [0.00; 0.13]		0.10 [0.02; 0.24]		0.10 [0.02; 0.24]			
White2001	31822	0.11 [0.08; 0.15]		0.00 [0.00; 0.01]		0.15 [0.11; 0.19]	0.01 [0.00; 0.02]	0.00 [0.00; 0.01]	
MacPherson2001	34407	0.00 [0.00; 0.01]		0.00 [0.00; 0.01]		0.01 [0.00; 0.02]	0.01 [0.00; 0.03]	0.00 [0.00; 0.01]	
Fixed effect		0.03 [0.02; 0.05]	0.02 [0.01; 0.05]	0.01 [0.00; 0.01]		0.06 [0.05; 0.08]	0.03 [0.02; 0.03]	0.01 [0.01; 0.02]	
Random effect		0.04 [0.01; 0.10]	0.03 [0.00; 0.13]	0.01 [0.00; 0.04]		0.12 [0.02; 0.28]	0.08 [0.00; 0.27]	0.02 [0.00; 0.18]	0.03 [0.00; 0.11]
tau²		0.0002	0.0001	0.0001		0.0002	0.0004	0.0001	
I²		90.3% [82.5%; 94.6%]	21.2% [0.0%; 91.8%]	58.1% [0.0%; 84.4%]		95.1% [92.0%; 96.9%]	96.8% [95.1%; 97.9%]	95.0% [90.3%; 97.5%]	
p-value Q-test		0.0001	0.2811	0.0489		0.0001	0.0001	0.0001	

Online supplementary appendix S7: Risks for different types of adverse events per 100 treatments as reported in single studies

Summary risk estimates of adverse events (AE) derived from random effects meta-analyses displayed in table 4